Evaxion Brings Three-Year EVX-01 Melanoma Data to ESMO 2026
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026, with durability data pending.
Topic
Esmo 2026
Topic
Topic
Topic
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026, with durability data pending.